114 related articles for article (PubMed ID: 20411345)
1. Modeling effect of a γ-secretase inhibitor on amyloid-β dynamics reveals significant role of an amyloid clearance mechanism.
Das R; Nachbar RB; Edelstein-Keshet L; Saltzman JS; Wiener MC; Bagchi A; Bailey J; Coombs D; Simon AJ; Hargreaves RJ; Cook JJ
Bull Math Biol; 2011 Jan; 73(1):230-47. PubMed ID: 20411345
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
[TBL] [Abstract][Full Text] [Related]
3. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
5. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
Lu Y; Zhang L; Nolan CE; Becker SL; Atchison K; Robshaw AE; Pustilnik LR; Osgood SM; Miller EH; Stepan AF; Subramanyam C; Efremov I; Hallgren AJ; Riddell D
J Pharmacol Exp Ther; 2011 Dec; 339(3):922-34. PubMed ID: 21930801
[TBL] [Abstract][Full Text] [Related]
6. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
7. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.
Portelius E; Van Broeck B; Andreasson U; Gustavsson MK; Mercken M; Zetterberg H; Borghys H; Blennow K
J Alzheimers Dis; 2010; 21(3):1005-12. PubMed ID: 20634579
[TBL] [Abstract][Full Text] [Related]
8. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.
Lanz TA; Karmilowicz MJ; Wood KM; Pozdnyakov N; Du P; Piotrowski MA; Brown TM; Nolan CE; Richter KE; Finley JE; Fei Q; Ebbinghaus CF; Chen YL; Spracklin DK; Tate B; Geoghegan KF; Lau LF; Auperin DD; Schachter JB
J Pharmacol Exp Ther; 2006 Nov; 319(2):924-33. PubMed ID: 16920992
[TBL] [Abstract][Full Text] [Related]
9. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
Anderson JJ; Holtz G; Baskin PP; Turner M; Rowe B; Wang B; Kounnas MZ; Lamb BT; Barten D; Felsenstein K; McDonald I; Srinivasan K; Munoz B; Wagner SL
Biochem Pharmacol; 2005 Feb; 69(4):689-98. PubMed ID: 15670587
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
[TBL] [Abstract][Full Text] [Related]
11. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice.
Asai M; Hattori C; Iwata N; Saido TC; Sasagawa N; Szabó B; Hashimoto Y; Maruyama K; Tanuma S; Kiso Y; Ishiura S
J Neurochem; 2006 Jan; 96(2):533-40. PubMed ID: 16336629
[TBL] [Abstract][Full Text] [Related]
12. Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T
Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP.
Boddapati S; Levites Y; Sierks MR
J Mol Biol; 2011 Jan; 405(2):436-47. PubMed ID: 21073877
[TBL] [Abstract][Full Text] [Related]
14. Thiamine deficiency increases β-secretase activity and accumulation of β-amyloid peptides.
Zhang Q; Yang G; Li W; Fan Z; Sun A; Luo J; Ke ZJ
Neurobiol Aging; 2011 Jan; 32(1):42-53. PubMed ID: 19233513
[TBL] [Abstract][Full Text] [Related]
15. First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates.
Sankaranarayanan S; Holahan MA; Colussi D; Crouthamel MC; Devanarayan V; Ellis J; Espeseth A; Gates AT; Graham SL; Gregro AR; Hazuda D; Hochman JH; Holloway K; Jin L; Kahana J; Lai MT; Lineberger J; McGaughey G; Moore KP; Nantermet P; Pietrak B; Price EA; Rajapakse H; Stauffer S; Steinbeiser MA; Seabrook G; Selnick HG; Shi XP; Stanton MG; Swestock J; Tugusheva K; Tyler KX; Vacca JP; Wong J; Wu G; Xu M; Cook JJ; Simon AJ
J Pharmacol Exp Ther; 2009 Jan; 328(1):131-40. PubMed ID: 18854490
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice.
Goldstein ME; Cao Y; Fiedler T; Toyn J; Iben L; Barten DM; Pierdomenico M; Corsa J; Prasad CV; Olson RE; Li YW; Zaczek R; Albright CF
J Pharmacol Exp Ther; 2007 Oct; 323(1):102-8. PubMed ID: 17640949
[TBL] [Abstract][Full Text] [Related]
17. Cisterna magna cannulated repeated CSF sampling rat model--effects of a gamma-secretase inhibitor on Aβ levels.
Shapiro JS; Stiteler M; Wu G; Price EA; Simon AJ; Sankaranarayanan S
J Neurosci Methods; 2012 Mar; 205(1):36-44. PubMed ID: 22226743
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.
Portelius E; Brinkmalm G; Tran AJ; Zetterberg H; Westman-Brinkmalm A; Blennow K
Neurodegener Dis; 2009; 6(3):87-94. PubMed ID: 19229112
[TBL] [Abstract][Full Text] [Related]
19. CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production.
Zhou S; Zhou H; Walian PJ; Jap BK
Proc Natl Acad Sci U S A; 2005 May; 102(21):7499-504. PubMed ID: 15890777
[TBL] [Abstract][Full Text] [Related]
20. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound.
Cook JJ; Wildsmith KR; Gilberto DB; Holahan MA; Kinney GG; Mathers PD; Michener MS; Price EA; Shearman MS; Simon AJ; Wang JX; Wu G; Yarasheski KE; Bateman RJ
J Neurosci; 2010 May; 30(19):6743-50. PubMed ID: 20463236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
